Nutritional Growth Solutions Ltd (NGS)

NGS Chart

vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Advanced

Show News Mov Avgs 9-day 10-day 20-day 30-day 50-day 100-day 150-day 200-day Mov Avgs 9-day 21-day 30-day 200-day Simple Exponential Weighted Simple Exponential Weighted vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day 9/21 Cross 10/30 Cross Golden Cross Vol RSI BB

Day 3m 6m 1yr 5yr 10yr

NGS's Principal Activity is the direct sale of products to end customers.

Announcements

Company Overview

Dividend History

Directors & Management

Name	Title	Since	Bio
Ms Lisa Wynne	Company Secretary	Dec 2020
Ms Liron Fendell	Chief Executive Officer,Managing Director	Oct 2020	Ms Liron Fendell Chief Executive Officer,Managing Director Ms Fendell has experience in nutrition, emerging technology and global child health. Ms Fendell was previously a corporate lawyer in one of Tel Aviv's law firms, representing bio tech start-ups as well as pharmaceutical companies, and gaining experience in structuring, negotiating and executing business transactions. Since 2012, Ms Fendell has served as a board member of CPC - Children Playing Chess, a non-profit organization. Struggling with her own children's nutrition and growth, Ms Fendell joined the Company on its creation in 2014 to work with the founding doctors at Schneider in order to convert the clinical knowledge and data into tangible products and commercial business.
Dr Kinneret Livnat Savitzky	Non-Executive Director	Oct 2020	Dr Kinneret Livnat Savitzky Non-Executive Director Dr Livnat Savitzky has experience in the life sciences industry, including drug discovery and development, corporate partnering and capital raising. Dr Livnat Savitzky currently serves as the CEO and a board member of FutuRx Ltd., an Israeli biotechnology accelerator established by OrbiMed Israel Partners. Johnson & Johnson Innovation and Takeda Ventures Inc. (the venture group of Takeda Pharmaceutical Company). Dr Livnat Savitzky also serves on the boards of several biotechnology or healthcare companies. From 2010 to 2016. Dr Livnat Savitzky served as the CEO of NASDAQ-listed BioLineRx Ltd. Prior to being appointed CEO of BioLineRx. she held various research and development management positions at BioLineRx and Compugen. She is also member of Risk Committee of the Company.
Dr Anton Uvarov	Non-Executive Director	Oct 2020	Dr Anton Uvarov Non-Executive Director Dr Uvarov has experience as an advisor to the healthcare industry with a focus on the biotechnology sector both in Australia and internationally, and has been involved in funding numerous biotechnology and pharmaceutical companies. He is a former equities research analyst with Citigroup, US. Dr Uvarov is a founding director of Actinogen Medical (ASX:ACW), a clinical stage biotechnology company and is an Executive Director of Neuroscientific Biopharmaceuticals (ASX:NSB), a biotechnology company developing new treatments for neurodegenerative diseases. Dr Uvarov is a former Director of Elsight Limited (ASX:ELS) and Parazero Limited (ASX:PRZ). He is also member of Risk Committee of the Company.
Mr Amir Zaidman	Non-Executive Director	Oct 2020	Mr Amir Zaidman Non-Executive Director Mr Zaidman has more than 20 years of experience in business development and venture capital investments. Since 2014, Mr Zaidman has served as the vice president of business development of "The Kitchen Hub" - the first FoodTech focused seed investor and technology incubator in Israel. In this capacity he provides business development and marketing support to portfolio companies and is also in charge of The Kitchen Hub's new investments, and has led the investment process in 18 portfolio companies to date. Mr Zaidman serves on the board of directors of numerous private FoodTech companies. Mr Zaidman is a executive in the FoodTech community in Israel. He created and manages the Israel FoodTech Innovation Linkedln group as well as the Israel's FoodTech Community MeetUp group. He is also Chair of Risk Committee of the Company.
Mr Brian Willoughby Leedman	Non-Executive Chairman,Non-Executive Director	Sep 2020	Mr Brian Willoughby Leedman Non-Executive Chairman,Non-Executive Director Mr Leedman is a marketing and investor relations executive with over 15 years of experience in the biotechnology I healthcare industry. He is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health (ASX:RAP) and Chairman of Neuroscientific Biopharmaceuticals (ASX:NSB). Previously, Mr Leedman co-founded Oncosil Medical Limited (ASX:OSL) and Biolife Science Limited (which was subsequently acquired by Imugene Limited (ASX:IMU)).Mr Leedman also served for ten years as Vice President (Investor Relations) at pSivida Corp, (now called Eyepoint Pharmaceuticals (NASDAQ:EYPT)). He was the Western Australian Chairman of AusBiotech, the association of biotechnology companies in Australia and formerly a non-executive Director at Alcidion Limited (ASX:ALC). Mr Leedman is a past winner of the 40Under40 Business Awards and represented ResApp Health as the global winner of Best Tech IPO' at the 2016 Talent Unleashed Awards culminating in spending a week in Silicon Valley with a judge for the Talent Unleashed Awards and the co-founder of Apple Corp., Steve Wozniak.
Professor Raanan Shamir	Chief Medical Officer,Executive Director	Jan 2014	Professor Raanan Shamir Chief Medical Officer,Executive Director Prof Shamir is Chairman of the Institute of Gastroenterology, Nutrition and Liver Diseases at Schneider. In the early 90s, he was a fellow at the Division of Pediatric Gastroenterology and Nutrition at The Children's Hospital of Philadelphia. Prof Shamir has published approximately 400 original papers, reviews and comments, book chapters and guidelines. His current research areas include paediatric nutrition, nutrition and growth, celiac disease, inflammatory bowel disease and childhood hyperlipidemia. Prof Shamir is a co-founder of the Company.

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Amir Zaidman	28/10/2020	0	N/A	N/A	N/A
Anton Uvarov	28/10/2020	N/A	1,689,290	N/A	N/A
Kinneret Livnat Savitzky	28/10/2020	0	N/A	N/A	N/A
Liron Fendell	28/10/2020	N/A	N/A	4,314,286	N/A
Brian Leedman	01/09/2020	N/A	1,807,143	N/A	N/A
Raanan Shamir	05/01/2014	4,465,470	N/A	1,114,286	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp)	2,444,775	5.68%
Netwealth Investments Limited (Super Services A/C)	1,666,060	3.87%
Citicorp Nominees Pty Limited	1,268,225	2.95%
Mr Anthony De Nicola & Mrs Tanya Louise De Nicola (De Nicola F)	1,125,000	2.61%
Netwealth Investments Limited (Wrap Services A/C)	986,872	2.29%
J P Morgan Nominees Australia Pty Limited	955,000	2.22%
Mr Narinder Singh Sudagar Singh (Sidhu A/C)	900,000	2.09%
Ms Kathryn Macdonald & Mr Christopher Stewart Macdonald	750,000	1.74%
Wolseley Road #1 Pty Limited (Adsaleum Family A/C)	650,000	1.51%
Mrs Elena Tsvetnenko (Yuri And Elena A/C)	637,500	1.48%
Kava Investments Pty Ltd (Rapid Trading A/C)	625,000	1.45%
Mr Christopher Stewart Macdonald	550,000	1.28%
Cosann Pty Ltd	500,000	1.16%
Mrs Christina Marie Hirrell	500,000	1.16%
Mr John Arharidis & Mrs Anna Arharidis	405,000	0.94%
Mr Yu He	395,386	0.92%
Upper Beach Pty Limited (Upper Beach S/F A/C)	340,000	0.79%
Mr Antony Sunna	325,000	0.76%
Mr Howard Nguyen	300,700	0.70%
Mr Terry James Gardiner	300,000	0.70%
Holism Pty Ltd	300,000	0.70%
Bond Street Custodians Limited (Vvalle - D42564 A/C)	300,000	0.70%
Samal Holdings Pty Ltd (Samal Family A/C)	300,000	0.70%
Mrs Lily Mah (Mj A/C)	299,900	0.70%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month